Bristol-Myers Squibb (BMY) Peer Comparison
$62.55
$0.23
(0.37%)
As on 13-Nov-2026 11:44EST
Market cap
$127,020 Mln
Revenue (TTM)
$50,034 Mln
P/E Ratio
13.8
P/B Ratio
5.5
Div. Yield
4 %
Edit
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
127,020 | 1,206,069 | 655,559 | 509,498 | 362,526 |
Revenue ($ Mln) |
50,034 | 86,462 | 99,335 | 66,014 | 67,302 |
Net Profit ($ Mln) |
9,243.00 | 27,579.70 | 16,095.00 | 10,350.00 | 2,453.00 |
Net Margin (%) |
18.47 | 31.90 | 16.20 | 15.68 | 3.64 |
RoE (%) |
42.53 | 77.18 | 19.78 | -- | 5.41 |
Price to Earnings |
13.78 | 43.95 | 41.32 | 49.53 | 148.42 |
Price-To-Book |
5.51 | 30.19 | 8.16 | 245.29 | 8.85 |
Income Statement ($ Mln)
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
50,034.00 | 86,462.00 | 99,335.00 | 66,014.00 | 67,302.00 |
|
Cost of Revenue
|
15,390.00 | 14,149.70 | 30,982.00 | 15,677.00 | 15,512.00 |
|
Gross Profit
|
34,259.00 | 54,127.00 | 63,937.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
21,598.00 | 32,481.90 | 42,828.00 | 26,879.00 | 40,863.00 |
|
Operating Profit (EBIT)
|
13,046.00 | 39,830.40 | 25,525.00 | 23,458.00 | 10,927.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
11,332.00 | 34,769.20 | 17,737.00 | 12,814.00 | 4,762.00 |
|
Provision for Tax
|
2,089.00 | 7,189.50 | 1,642.00 | 2,466.00 | 2,313.00 |
|
Profit after Tax (Net Income)
|
9,243.00 | 27,579.70 | 16,095.00 | 10,350.00 | 2,453.00 |
|
Minority Interest
|
1.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Consolidated Profit
|
1,087.00 | 6,636.00 | 5,116.00 | 0.00 | 2,963.00 |
Liabilities ($ Mln)
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
23,404.00 | 40,271.00 | 81,529.00 | -5,935.00 | 44,893.00 |
|
Minority Interest
|
1.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Non-Current Liabilities
|
46,615.00 | 60,805.00 | 60,439.00 | 99,361.00 | 59,026.00 |
|
Current Liabilities
|
18,753.00 | 46,996.00 | 55,457.00 | 41,642.00 | 28,801.00 |
|
Total Liabilities
|
90,038.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
59,005.00 | 82,809.00 | 141,074.00 | 101,446.00 | 93,832.00 |
|
Current Assets
|
29,767.00 | 65,263.00 | 56,351.00 | 33,669.00 | 38,941.00 |
|
Total Assets
|
90,038.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
44,810.00 | 49,503.00 | 44,651.00 | 70,822.00 | 53,777.00 |
|
Net Current Assets
|
11,014.00 | 18,267.00 | 894.00 | -7,973.00 | 10,140.00 |
Cashflow ($ Mln)
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
14,156.00 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-4,132.00 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-10,348.00 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.60 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
42.53 | 77.18 | 19.78 | 6,214.71 | 5.41 |
|
ROA (%)
|
7.95 | 15.75 | 6.48 | 5.85 | 1.53 |
|
EBIT Margin (%)
|
25.95 | 49.24 | 18.85 | 26.50 | 9.28 |
|
Net Margin (%)
|
18.47 | 31.90 | 16.20 | 15.68 | 3.64 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.16 | 45.51 | 7.80 | 10.68 | 4.79 |
|
EBIT Growth (%)
|
30.01 | 70.32 | -41.80 | 285.20 | -72.96 |
|
Net Profit Growth (%)
|
53.06 | 49.79 | -35.92 | 333.42 | -87.11 |
|
EPS Growth (%)
|
52.35 | 50.65 | -36.38 | 333.38 | -87.04 |
|
Book Value Growth (%)
|
25.23 | 70.28 | 2.00 | -4,203.16 | -12.72 |
Valuation Ratios
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.61 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
5.96 | 36.37 | 6.19 | -125.57 | 4.98 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
9.62 | 31.56 | 12.97 | 26.61 | 10.54 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.79 | 1.17 | 0.44 | -10.53 | 1.11 |
|
Short term debt to equity ratio
|
0.05 | 0.06 | 0.11 | -1.41 | 0.09 |
|
Current Ratio
|
1.59 | 1.39 | 1.02 | 0.81 | 1.35 |
|
Quick Ratio
|
1.44 | 1.00 | 0.74 | 0.69 | 1.14 |
|
Interest Coverage
|
7.86 | 30.52 | 23.23 | 5.45 | 3.43 |
Operating Efficiency Ratios
| Bristol-Myers Squibb (BMY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.26 | 29.18 | 19.11 | 20.94 | 18.94 |
|
Asset Turnover
|
0.43 | 0.49 | 0.40 | 0.37 | 0.42 |
|
Receivable days
|
109.70 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
68.76 | 352.51 | 160.77 | 91.61 | 128.14 |
|
Payable days
|
94.05 | 142.23 | 134.61 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
84.40 | 303.95 | 96.16 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
